Gary L. Smith joined Boomerang Ventures as an Executive-in-Residence for the Boomerang Studio. He has successfully led multiple medical technology and life sciences start-ups from concept through market entry and growth.
With unlimited energy and enthusiasm, Gary brings a robust combination of medical industry knowledge, business-technology strategy, and entrepreneurial drive. He has developed significant technology commercialization expertise while nurturing strong relationships with clinical, technology, and investment leaders worldwide.
Gary is the Founder and Managing Director of Life Sciences Technology Group, Ltd., an innovative med-tech/life science technology commercialization consulting enterprise. He is President and Chief Executive Officer of INFINITY Angioplasty BalloonTM Co, an early commercial-stage medical device company developing innovative catheter-based technologies for the treatment of peripheral artery disease, and Principal Investigator for ThermoMorph, QuickflowTM LLC., an early-stage MedTech company focused on endovascular mechanical embolectomy. Additionally, he serves as an Executive in Residence for ProMedica Health Systems Innovations, evaluating emerging technology commercialization opportunities for the healthcare system. In prior work, Gary served as founding CEO of VentureMed Group, Inc., guiding the Company from concept to commercialization in the US and EU, raising over $20M through Series B. Gary served as CEO of CleveX, Inc., a surgical suture-less skin biopsy platform for melanoma detection, which he co-founded with the Cleveland Clinic Innovations; and Interim CEO for Prognostix, LLC, a cardiac biomarker diagnostic company founded at the Cleveland Clinic, which later became Cleveland Heart Labs.
Before embarking on his journey with medical technology start-ups, Gary held the position of Vice President at Battelle Memorial Institutes Life Science group. During his tenure, he was instrumental in commercial medical research, technology development and commercialization, fostering collaborations between Fortune 50 medical companies worldwide and five key DOE National Laboratories across the US.
Gary holds a BS in Human Physiology and an MBA in Marketing and Finance from the University of Toledo; he completed graduate studies (Ph.D.) in Cardiovascular Physiology (ABD) from the Medical College of Ohio and postgraduate studies in Technology Entrepreneurship at Temple University, Philadelphia. Additionally, he recently completed an Executive Leadership Certificate Course from The Wharton School – Institute of Executive Education. Gary has served on dozens of boards and advisory roles for industry-leading companies.